- Home
- TYG vs ALXO Comparison
TYG vs ALXO Comparison
Compare TYG & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYG
- ALXO
- Stock Information
- Founded
- TYG 2003
- ALXO 2015
- Country
- TYG United States
- ALXO United States
- Employees
- TYG N/A
- ALXO N/A
- Industry
- TYG Investment Managers
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- TYG Finance
- ALXO Health Care
- Exchange
- TYG Nasdaq
- ALXO Nasdaq
- Market Cap
- TYG 429.9M
- ALXO 81.1M
- IPO Year
- TYG N/A
- ALXO 2020
- Fundamental
- Price
- TYG $40.45
- ALXO $1.51
- Analyst Decision
- TYG
- ALXO Strong Buy
- Analyst Count
- TYG 0
- ALXO 6
- Target Price
- TYG N/A
- ALXO $14.20
- AVG Volume (30 Days)
- TYG 28.5K
- ALXO 518.7K
- Earning Date
- TYG 01-01-0001
- ALXO 11-11-2024
- Dividend Yield
- TYG 7.71%
- ALXO N/A
- EPS Growth
- TYG N/A
- ALXO N/A
- EPS
- TYG 9.77
- ALXO N/A
- Revenue
- TYG $13,618,248.00
- ALXO N/A
- Revenue This Year
- TYG N/A
- ALXO N/A
- Revenue Next Year
- TYG N/A
- ALXO N/A
- P/E Ratio
- TYG $4.13
- ALXO N/A
- Revenue Growth
- TYG N/A
- ALXO N/A
- 52 Week Low
- TYG $27.25
- ALXO $1.42
- 52 Week High
- TYG $41.46
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- TYG 62.11
- ALXO 30.69
- Support Level
- TYG $40.05
- ALXO $1.42
- Resistance Level
- TYG $40.58
- ALXO $1.62
- Average True Range (ATR)
- TYG 0.59
- ALXO 0.12
- MACD
- TYG -0.12
- ALXO 0.03
- Stochastic Oscillator
- TYG 64.06
- ALXO 15.79
About TYG Tortoise Energy Infrastructure Corporation
Tortoise Energy Infrastructure Corp seeks to provide a high level of current income to stockholders. It invests in fixed-income and dividend-paying equity securities of power and energy infrastructure companies that provide stable and defensive characteristics throughout economic cycles.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.